Number of Treatment Cycles Influences Development of Cytotoxic T Cells in Metastatic Breast Cancer Patients – A Phase I/II Study

REFERENCES

• Apostolopoulos, V., Osinski, C., McKenzie, I.F. (1998). MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral [see comments]. Nat. Med. 4:315–320.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos, V., Barnes, N., Pietersz, G. A., McKenzie, I.F. (2000). Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18:3174–3184.
   PubMed Web of Science ®Google Scholar
• Barnd, D. L., Lan, M. S., Metzgar, R. S., Finn, O. J. (1989). Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86:7159–7163.
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program; DCTD; NCI; NIH; DHHS (1998): Common Toxicity Criteria, Version 2.0 (CTC). (Available at: http://ctep.info.nih.gov/reporting/ctc.html [Accessed April 30, 1999; Cancer Therapy Evaluation Program).
   Google Scholar
• Chang, A. E., Yoshizawa, H., Sakai, K., Cameron, M. J., Sondak, V. K., Shu, S. (1993). Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53:1043–1050.
   PubMed Web of Science ®Google Scholar
• den Haan, J. M., Meadows, L. M., Wang, W., Pool, J., Blokland, E., Bishop, T. L., Reinhardus, C., Shabanowitz, J., Offringa, R., Hunt, D. F., Engelhard, V. H., Goulmy, E. (1998). The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054–1057.
   PubMed Web of Science ®Google Scholar
• Drobyski, W. R., Keever, C. A., Roth, M. S., Koethe, S., Hanson, G., McFadden, P., Gottschall, J. L., Ash, R. C., van Tuinen, P., Horowitz, M. M., (1993). Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310–2318.
   PubMed Web of Science ®Google Scholar
• Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J. P., Citrin, D. E., Leitman, S. F., Wunderlich, J., Restifo, N. P., Thomasian, A., Downey, S. G., Smith, F. O., Klapper, J., Morton, K., Laurencot, C., White, D. E., Rosenberg, S.A. (2008): Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32):5233–5239.
   PubMed Web of Science ®Google Scholar
• Falkenburg, J. H., Wafelman, A. R., Joosten, P., Smit, W. M., van Bergen, C. A., Bongaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J. E., Kluin-Nelemans, H. C., Fibbe, W. E., Willemze, R. (1999). Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94:1201–1208.
   PubMed Web of Science ®Google Scholar
• Fass, L., Fefer, A. (1972). Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res. 32:997–1001.
   PubMed Web of Science ®Google Scholar
• Fefer, A., Sullivan, K. M., Weiden, P., Buckner, C. D., Schoch, G., Storb, R., Thomas, E. D. (1987). Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 244:401–408.
   PubMedGoogle Scholar
• Gendler, S. J., Spicer, A. P., Lalani, E. N., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Boshell, M., Taylor-Papadimitriou, J. (1991). Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis. 144:S42–S47.
   PubMed Web of Science ®Google Scholar
• Habib-Agahi, M., Phan, T. T., Searle, P. F. (2007). Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol. 19(12):1383–94. Epub 2007 Oct 31.
   PubMed Web of Science ®Google Scholar
• Higano, C. S., Brixey, M., Bryant, E. M., Durnam, D. M., Doney, K., Sullivan, K. M., Singer, J. W. (1990). Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50:175–177.
   PubMed Web of Science ®Google Scholar
• Hiltbold, E. M., Ciborowski, P., Finn, O. J. (1998). Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 58:5066–5070.
   PubMed Web of Science ®Google Scholar
• Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., Yee, C. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358:2698–2703.
   PubMed Web of Science ®Google Scholar
• Ioannides, C. G., Fisk, B., Jerome, K. R., Irimura, T., Wharton, J. T., Finn, O. J. (1993). Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151:3693–3703.
   PubMed Web of Science ®Google Scholar
• Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F., Bast, R. C., Jr., Finn, O. J. (1991). Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908–2916.
   PubMed Web of Science ®Google Scholar
• Jin, Y., Giri, C., Klutch, M.J., Shepp, D., Wright, S.E. (1993). Improved immunogenicity of recombinant vaccinia virus-anchored gp120 lacking gp41. Vaccine 11:1280–1282.
   PubMed Web of Science ®Google Scholar
• Karanikas, V., Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., McKenzie, I. F. (1997). Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100:2783–2792.
   PubMed Web of Science ®Google Scholar
• Kolb, H. J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., Wilmanns, W. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465.
   PubMed Web of Science ®Google Scholar
• Kornbluth, J., Flomenberg, N., Dupont, B. (1982). Cell surface phenotype of a cloned line of natural killer cells. J. Immunol. 129:2831–2837.
   PubMed Web of Science ®Google Scholar
• Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., Andreesen, R. (2006). Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24:5060–5069.
   PubMed Web of Science ®Google Scholar
• Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., Mackensen, A. (2003). Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2161–2169.
   PubMed Web of Science ®Google Scholar
• Mitchell, M. S., Darrah, D., Yeung, D., Halpern, S., Wallace, A., Voland, J., Jones, V., Kan-Mitchell, J. (2002). Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20: 1075–1086.
   PubMed Web of Science ®Google Scholar
• Odom, L. F., August, C. S., Githens, J. H., Humbert, J. R., Morse, H., Peakman, D., Sharma, B., Rusnak, S. L., Johnson, F. B. (1978). Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man? Lancet 2:537–540.
   PubMed Web of Science ®Google Scholar
• Prenndergast, G. C., Jaffee, E. M. (2007). Cancer Immunotherapy: Immune Suppression and Tumor Growth, 13th ed. Academic Press/Elsevier:Amsterdam, 2007.
   Google Scholar
• Pulvertaft, R. J. V. (1964). Cytology of Burkitt's tumour (Afrikan Lymphoma). Lancet 1:238–240.
   PubMed Web of Science ®Google Scholar
• Quinlin, I. S., Burnside, J. S., Dombrowski, K. E., Phillips, C. A., Dolby, N., Wright, S. E. (2007). Context of MUC1 epitope: immunogenicity. Oncol. Rep. 17:453–456
   Google Scholar
• Roskrow, M.A., Suzuki, N., Gan, Y.j, Sixbey, J.W., Ng, C.Y., Kimbrough, S., Hudson, M., Brenner, M.K., Heslop, H.E., Rooney, C.M. (1998). Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91:2925–2934.
   PubMed Web of Science ®Google Scholar
• Ross, S., Osband, M. (1989). Treatment of metastatic renal cell carcinoma (RCC) with autloymphocyte therapy. Correlation between survival and the number of infused lymphocytes. FASEB J. 3(3, Part 1):A825 (Abstr 3482).
   Google Scholar
• Straathof, K. C. M., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M., V, Gee, A. P., Russell, H., V, Brenner, M. K., Rooney, C. M., Heslop, H. E. (2005): Treatment of nasopharyngeal carcinoma with Epstein-Barr virus—specific T lymphocytes. Blood 2005 Mar 1,105(5):1898–1904. Epub 2004 Nov 12.
   PubMed Web of Science ®Google Scholar
• Sullivan, K. M., Weiden, P. L., Storb, R., Witherspoon, R. P., Fefer, A., Fisher, L., Buckner, C. D., Anasetti, C., Appelbaum, F. R., Badger, C., (1989). Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728.
   PubMed Web of Science ®Google Scholar
• Toh, U., Yamana, H., Sueyoshi, S., Tanaka, T., Niiya, F., Katagiri, K., Fujita, H., Shirozou, K., Itoh, K. (2000). Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin. Cancer. Res. 6:4663–4673.
   PubMed Web of Science ®Google Scholar
• Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. L., Linehan, W. M., Lotze, M. T., Robertson, C. N., Seipp, C.A., Simon, P., (1988). Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839–853.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Vesole, D. H., Jagannath, S., Hilton, J., Munshi, N., Barlogie, B. (1996). Graft-versus-myeloma effect: proof of principle. Blood 87:1196–1198.
   PubMed Web of Science ®Google Scholar
• Ueno, N. T., Rondon, G., Mirza, N. Q., Geisler, D. K., Anderlini, P., Giralt, S. A., Andersson, B. S., Claxton, D. F., Gajewski, J. L., Khouri, I. F., Korbling, M., Mehra, R. C., Przepiorka, D., Rahman, Z., Samuels, B. I., van Besien, K., Hortobagyi, G. N., Champlin, R. E. (1998). Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16:986–993.
   PubMed Web of Science ®Google Scholar
• Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., Riddell, S. R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038–1044.
   PubMed Web of Science ®Google Scholar
• Wright, S. E., Kilinski, L., Talib, S., Lowe, K. E., Burnside, J. S., Wu, J. Y., Dolby, N., Dombrowski, K. E., Lebkowski, J. S., Philip, R. (2000). Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J. Immunother. 23:2–10.
   Google Scholar
• Wright, S. E., Khaznadar, R., Wang, Z., Quinlin, I. S., Rewers-Felkins, K. A., Phillips, C. A., Patel, S. (2008). Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand. J. Immunol. Jan 67(1):24–29.
   PubMed Web of Science ®Google Scholar
• Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168–16173.
   PubMed Web of Science ®Google Scholar
• Zhou, J., Shen, X, Huang, J., Hodes, R. J., Rosenberg, S. A., Robbins, P. F. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175:7046–7052.
   PubMed Web of Science ®Google Scholar